WilmerHale Guides Corvia Medical in $35M Strategic Investment by Edwards Lifesciences

WilmerHale Guides Corvia Medical in $35M Strategic Investment by Edwards Lifesciences

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, has entered into an agreement with Edwards Lifesciences. The agreement includes a $35 million investment and provides the exclusive option for Edwards to acquire the company at a later date. Funds will be used to complete the REDUCE LAP-HF II clinical trial of the InterAtrial Shunt Device (IASD®), the world's first transcatheter device for the treatment of heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF).

The WilmerHale team representing Corvia in this transaction was led by Jason Kropp and includes Bill Caporizzo, Belinda Juran, Scott Kilgore, Hal Leibowitz, Bruce Manheim, George Shuster, Kimberly Wethly, Andrew Langworthy, Alex Civetta, Byron Crowe, Todd Rosenthal and Ben Kelsey.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel